Research progress in treatment of ulcerative colitis based on Th17,Treg and Th17/Treg balance
Ulcerative colitis is a major type of the inflammatory bowel disease.And because the pathogenesis is still uncertain,there are numerous studies about its pathogenesis at present.Due to the large side effects of the traditional medicines and the limitations of their usage,the development of the new safe and effective drugs has become an urgent need.And many studies has shown that the occurrence and development of the ulcerative colitis has correlated with the Th17/Treg balance closely.In the state of inflammatory bowel disease,some pathogens break through the intestinal epithelial barrier and subsequently activate antigen-presenting cells.The resulting CD4+T cells are prone to produce more Th 17 cells,which will continue to accumulate excessive inflammatory cytokines.At this time,this effect will far exceed the immune tolerance of Treg,and this phenomenon of mutual inhibition and maintaining balance will be broken,as a result,tissue inflammation is increased,and intestinal mucosal tissue is destroyed.Therefore,restoring this balance is critical to the relief of ulcerative colitis.At present,many studies have analyzed the pathways related to the regulation of Th17 expression from different perspectives,analyzed many ways to restore Treg expression,and explored the specific mechanism of restoring Th17/Treg balance from microbial regulation,targeted drugs for different receptors,and traditional Chinese medicine treatment.And good progress has been made,many drugs have even been used in clinical trials.Therefore,this article summarizes the therapy research based on Th 17,Treg,and Th17/Treg balance in recent years,and provides help for more researchers to clearly understand the current research results,and looks forward to finding more therapeutic drugs with high cure rate and less toxic and side effects that can be applied to the clinic.
万方数据
维普
